BETA Technologies launches IPO of 25 million shares priced $27-$33
Director Joseph H. Wender of Ionis Pharmaceuticals Inc (NASDAQ:IONS) sold a total of 28,000 shares of common stock in a series of transactions on September 2nd and 3rd, 2025, for approximately $1.6 million. The sales, executed under a pre-arranged Rule 10b5-1 trading plan, occurred at weighted average prices ranging from $55.0386 to $60.1383 per share. The transactions come as the stock has shown remarkable strength, gaining 39.2% in the past week and 75.8% over six months, according to InvestingPro data.
On September 2, Wender sold 11,200 shares at a weighted average price of $55.0386, in a range of $55.000 to $55.180, and a further 5,600 shares at a weighted average price of $57.5311, in a range of $57.500 to $57.575. On September 3, 11,200 shares were sold at a weighted average price of $60.1383, in a range of $60.00 to $60.53.
Following these transactions, Wender’s indirectly held ownership in Ionis Pharmaceuticals stands at 108,835 shares.
In other recent news, Ionis Pharmaceuticals has reported significant developments that have captured the attention of investors and analysts alike. The company announced positive topline results from its Phase 3 CORE and CORE2 trials for the treatment of severe hypertriglyceridemia. These trials demonstrated notable benefits in triglyceride lowering and reducing the risk of acute pancreatitis, described by Bernstein SocGen Group as exceeding high expectations. Following these results, several financial firms have adjusted their outlooks on Ionis Pharmaceuticals. RBC Capital raised its price target to $80, citing the potential of Ionis’ pancreatitis drug, while H.C. Wainwright increased its target to $95, highlighting strong triglyceride reductions in pivotal studies. Additionally, BMO Capital upgraded the stock to Outperform, reflecting optimism about Olezarsen’s potential as a blockbuster drug. Oppenheimer also raised its price target to $81, maintaining an Outperform rating based on the positive trial outcomes for Tryngolza. These recent developments underscore the growing confidence in Ionis Pharmaceuticals’ therapeutic advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.